Slide 1: PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information
PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information April 30, 2026 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer 2 This presentation by Contineum Therapeutics, Inc. (“Contineum”, “We” or “Our) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical facts contained in this presentation, includin
Slide 3: PIPE-791 Demonstrated a Favorable Safety and Tolerability Profile and Consistent Improvement Across Multiple Exploratory Pain Measures
• Phase 1b randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients – 23 chronic osteoarthritis pain (COAP) and 20 chronic lower back pain (CLBP) • Favorable safety and tolerability demonstrated at the once-daily 10mg oral dose in the largest patient population and
Slide 4: Clinical Trial Schema
Clinical Trial Schema(1) Primary endpoint for safety & tolerability Multiple exploratory endpoints for pain assessment COAP, n = 22 CLBP, n = 20 COAP, n = 21 CLBP, n = 19 Wash-out Run-in (baseline) PIPE-791 (10 mg, QD) Crossover Placebo Placebo PIPE-791 (10 mg, QD) Treatment Period 1 (TP1) Treatment
Slide 5: Similar Demographics and Disease Characteristics Across Treatment Groups
5 Similar Demographics and Disease Characteristics Across Treatment Groups – Participants with Moderate Chronic Pain Demographics & Baseline Pain Characteristics * PIPE-791 (N=21) Placebo (N=22) Total (N=43) Age (years) 57.1 (10.2) 57.9 (8.8) 57.5 (9.4) Female Sex n (%) 11 (52.4%) 14 (63.6%) 25 (58.
Slide 6: PIPE-791 Demonstrated a Favorable Safety & Tolerability Profile
Sy st ol ic B P (m m H g) 160 140 120 100 Baseline Day 8 Day 36End of TP1* End of TP2 PIPE-791 Placebo PIPE-791 PIPE-791 PIPE-791 PIPE-791Placebo Placebo Placebo Placebo 6 PIPE-791 Demonstrated a Favorable Safety & Tolerability Profile • The most common TEAEs were headache (n=3) and fatigue (n=2) •
Slide 7: PIPE-791 Produced Consistent and Sustained Improvements in PI-NRS Measures of Average Daily Pain for COAP
7 PIPE-791 Produced Consistent and Sustained Improvements in PI-NRS Measures of Average Daily Pain for COAP in TP1 and TP2 Mean Change from Baseline (95% CI) in Weekly Average of Average Daily Pain (TP1 and TP2) -1.32 -1.50 -1.53 -1.60 -0.51 -0.86 -1.31 -1.27 -2.8 -2.4 -2.0 -1.6 -1.2 -0.8 -0.4 0.0 0
Slide 8: PIPE-791 Produced Consistent and Sustained Improvements in PI-NRS Measures of Worst Daily Pain for COAP
8 PIPE-791 Produced Consistent and Sustained Improvements in PI-NRS Measures of Worst Daily Pain for COAP in TP1 and TP2 -1.36 -1.90 -1.90 -1.99 -0.36 -0.66 -1.13 -1.00 -3.6 -3.2 -2.8 -2.4 -2.0 -1.6 -1.2 -0.8 -0.4 0.0 0.4 0.8 1.2 M ea n (9 5% C I) C ha ng e fr om B as el in e COAP – TP1 PIPE-791 (n=
Slide 9: PIPE-791 Increased the Number of Patients Displaying a Clinically Meaningful Reduction in Average Chronic Pain for COAP
30% ≥ Greater Reduction From Baseline In Weekly Average of Average Daily PI-NRS (COAP at End of TP1 & TP2) 45.5% 45.5% 27.3% 44.4% 0% 20% 40% 60% End of TP1 End of TP2 Pe rc en ta ge o f R es po nd er s (% ) Treatment Period Endpoint COAP PIPE-791 (n=11) Placebo (n=11) 9 PIPE-791 Increased the Numbe
Slide 10: Supportive Evidence from Modified KOOS Demonstrates a Potential for Functional Improvement In Patients with COAP
Modified KOOS in COAP Treatment Period 1 PIPE-791 (N = 11) Placebo (N = 11) Baseline Modified KOOS* 59.36 (9.65) 54.28 (15.39) Change From Baseline 95% CI † +10.56 (3.62, 17.50) +6.28 (-2.63, 15.20) Treatment Period 2 PIPE-791 (N = 11) Crossover Placebo (N = 10) Baseline Modified KOOS* 60.56 (20.86)
Slide 11: PIPE-791 Treatment Demonstrated Numerical Improvements in Treatment Period 1
TP1 COAP CLBP Average Daily Pain PIPE-791 (N= 11) Placebo (N =11) PIPE-791 (N = 10) Placebo (N = 10) Baseline Weekly Average PI-NRS * 5.58 (1.21) 6.23 (1.43) 5.60 (1.27) 5.57 (1.50) Change From Baseline 95% CI † -1.60 (-2.49, -0.72) -1.27 (-2.15, -0.39) -1.33 (-1.83, -0.84) -0.55 (-1.33, 0.22) Worst
Slide 12: Treatment Period 2 Pain Results for COAP and CLBP
TP2 COAP CLBP Average Daily Pain PIPE-791 (N = 11) Crossover Placebo (N = 10) PIPE-791 (N = 9) Crossover Placebo (N = 10) Baseline Weekly Average PI-NRS * 4.96 (2.21) 3.56 (1.45) 4.72 (1.89) 4.75 (1.81) Change From Baseline 95% CI † -1.42 (-2.28, -0.56) -0.74 (-1.83, 0.35) 0.13 (-0.68, 0.94) -0.55 (
Slide 13: PIPE-791 – A Differentiated Brain-Penetrant LPA1 Antagonist with Broad Therapeutic Potential
13 PIPE-791 – A Differentiated Brain-Penetrant LPA1 Antagonist with Broad Therapeutic Potential Fibrosis • LPA1 clinical validation in IPF/PPF • Differentiated profile including target coverage and tolerability • Brain penetrance may address fibrosis and pain burden including comorbid age-related pa
Slide 14: PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information
PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information April 30, 2026